- Stocks
- Pharma & Healthcare
- Max Healthcare Institute
Max Healthcare Institute share price
NSE: MAXHEALTHPharma & HealthcareMedical Care Facilities
Max Healthcare Institute at a glance
Max Healthcare Institute (NSE: MAXHEALTH) closed at ₹804.80 on 22 Oct 2026, down 1.54% on the day. With a market capitalisation of ₹78,327 Cr, it ranks 137th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 54.6× trailing earnings, against a return on equity of 13.4% in FY26. Over the past year the share price has fallen 30.6%. Its 52-week range is ₹801.05 (22 Oct 2026) to ₹1,221.90 (23 Oct 2025); the last close is 34.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2,143 Cr (+12.2% year on year) and net profit ₹342 Cr (+7.3%), on a consolidated basis. Promoters held 23.71% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹78,327 CrRank 137 on NSE
- P/E (trailing)
- 54.6×
- Price to book
- 8.71×FY26
- EPS (TTM)
- ₹14.84to Q4 FY26
- ROE
- 13.4%FY26
- ROCE
- 13.0%FY26
- Debt to equity
- 0.27FY26
- Net profit margin
- 17.2%FY26
- Book value / share
- ₹110.43FY26
- Dividend payout
- 10.1%FY26
- 52-week high
- ₹1,221.9023 Oct 2025
- 52-week low
- ₹801.0522 Oct 2026
- 1-year return
- −30.6%
- RSI (14-day)
- 19.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.54% | −5.8% | −24.6% | −25.5% | −30.6% |
Max Healthcare Institute quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,543 Cr | ₹1,707 Cr | ₹1,868 Cr | ₹1,910 Cr | ₹2,028 Cr | ₹2,135 Cr | ₹2,068 Cr | ₹2,143 Cr |
| Revenue YoY | +20.1% | +25.3% | +40.0% | +34.2% | +31.4% | +25.1% | +10.7% | +12.2% |
| Net profit | ₹236 Cr | ₹282 Cr | ₹239 Cr | ₹319 Cr | ₹308 Cr | ₹491 Cr | ₹301 Cr | ₹342 Cr |
| Net profit YoY | −1.6% | +1.9% | −17.5% | +26.8% | +30.3% | +74.3% | +26.0% | +7.3% |
| Net margin | 15.3% | 16.5% | 12.8% | 16.7% | 15.2% | 23.0% | 14.6% | 16.0% |
| EPS | ₹2.43 | ₹2.90 | ₹2.46 | ₹3.28 | ₹3.17 | ₹5.05 | ₹3.10 | ₹3.52 |
Max Healthcare Institute financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹2,505 Cr | ₹3,931 Cr | ₹4,563 Cr | ₹5,406 Cr | ₹7,028 Cr | — |
| Operating profit | ₹165 Cr | ₹748 Cr | ₹1,064 Cr | ₹1,365 Cr | ₹1,480 Cr | — |
| Net profit | −₹115 Cr | ₹605 Cr | ₹1,104 Cr | ₹1,058 Cr | ₹1,076 Cr | — |
| EPS (₹) | −₹2.00 | ₹6.00 | ₹11.00 | ₹11.00 | ₹11.00 | — |
| Cash from operations | ₹118 Cr | ₹748 Cr | ₹1,209 Cr | ₹1,122 Cr | ₹1,459 Cr | — |
| Total debt | ₹843 Cr | ₹629 Cr | ₹497 Cr | ₹1,061 Cr | ₹2,270 Cr | ₹2,439 Cr |
| Shareholders' equity | ₹5,639 Cr | ₹6,282 Cr | ₹7,410 Cr | ₹8,408 Cr | ₹9,381 Cr | ₹10,747 Cr |
Max Healthcare Institute shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 23.74% | 23.74% | 23.74% | 23.72% | 23.71% | 23.71% |
| Foreign institutions | 54.74% | 54.76% | 51.80% | 50.55% | 45.39% | 41.78% |
| Domestic institutions | 17.58% | 17.42% | 20.03% | 21.20% | 26.32% | 29.96% |
| Non-institutions | 3.94% | 4.08% | 4.43% | 4.52% | 4.57% | 4.56% |
Max Healthcare Institute vs peers
The listed Pharma & Healthcare companies nearest to Max Healthcare Institute by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DRREDDYDr. Reddy's Laboratories | ₹1,236.20 | −0.26% | +0.0% | ₹1,03,183 Cr | — | — |
| MANKINDMankind Pharma | ₹2,236.60 | −1.69% | −8.1% | ₹92,371 Cr | 48.4 | — |
| AUROPHARMAAurobindo Pharma | ₹1,571.30 | −0.01% | +40.0% | ₹90,409 Cr | 26 | — |
| LUPINLupin | ₹1,929.60 | −0.64% | −0.3% | ₹88,228 Cr | 16.6 | — |
| MAXHEALTHMax Healthcare Institute | ₹804.80 | −1.54% | −30.6% | ₹78,327 Cr | 54.6 | — |
| GLENMARKGlenmark Pharmaceuticals | ₹2,196.40 | −0.16% | +16.4% | ₹61,983 Cr | 45.5 | — |
| ALKEMAlkem Laboratories | ₹4,972.00 | −0.58% | −9.6% | ₹59,448 Cr | 25.8 | — |
Ask anything about Max Healthcare Institute
Pivot answers on the live chart with evidence you can check, and tests strategies against MAXHEALTH's own history. Try: “Why has MAXHEALTH moved over the last three months?” · “Backtest a 50-day moving-average crossover on MAXHEALTH over five years” · “Compare MAXHEALTH with DRREDDY on margins and valuation”
Frequently asked questions about Max Healthcare Institute
What is the share price of Max Healthcare Institute today?
Max Healthcare Institute (NSE: MAXHEALTH) last closed at ₹804.80 on 22 Oct 2026. Its 52-week high is ₹1,221.90 and its 52-week low is ₹801.05.
What is the market cap of Max Healthcare Institute?
Max Healthcare Institute's market capitalisation is ₹78,327 Cr (₹78,327 Cr) at the 22 Oct 2026 close, ranking 137th among the NSE companies Pivot tracks.
What is the P/E ratio of Max Healthcare Institute?
Max Healthcare Institute trades at a trailing P/E of 54.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.
What is the ROE and ROCE of Max Healthcare Institute?
Return on equity was 13.4% in FY26 and return on capital employed was 13.0% in FY26 (consolidated figures).
Is Max Healthcare Institute a debt-free company?
No. Max Healthcare Institute's debt-to-equity ratio was 0.27 in FY26, with total debt of ₹2,439 Cr.
What were Max Healthcare Institute's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Max Healthcare Institute reported revenue of ₹2,143 Cr, +12.2% year on year, and net profit of ₹342 Cr, +7.3% year on year.
How has Max Healthcare Institute stock performed over the last year?
Max Healthcare Institute's share price has fallen 30.6% over the past year, −25.5% over three months and −24.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Max Healthcare Institute?
As of 30 Jun 2026: promoters 23.71%, foreign institutions 41.78%, domestic institutions 29.96%, non-institutions 4.56%.
Who are Max Healthcare Institute's competitors?
The listed Pharma & Healthcare companies closest to Max Healthcare Institute by market cap are Dr. Reddy's Laboratories, Mankind Pharma, Aurobindo Pharma, Lupin, Glenmark Pharmaceuticals and Alkem Laboratories.
Is Max Healthcare Institute a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Max Healthcare Institute's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MAXHEALTH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text